Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds
30 Juin 2022 - 8:00PM
Negma Group has converted 180 convertible bonds
resulting in a EUR 450,000 capital increase and Kreos/Pontifax
convertible bonds have been reimbursed in an amount of EUR 3
million
Leuven,
BELGIUM, Boston, MA, US
– June 30 ,
2022 –
8.00
PM CET – In accordance with
article 15 of the Belgian Act of May 2, 2007 on the disclosure of
major participations in issuers of which shares are admitted to
trading on a regulated market and regarding miscellaneous
provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or
“Oxurion”), announces the below information concerning the
conversion of the Negma bonds, following the issuance of 1,216,216
new ordinary shares on June 7 (as listed on June 9), 2022, for a
total amount of EUR 450,000, as the result of the conversion of 180
convertible bonds pursuant to the Capital Commitment entered into
with Negma Group.
Following completion of the capital increase
through the conversion of the Negma convertible bonds the total
number of shares issued by Oxurion amounts to 49,821,189
outstanding ordinary shares carrying voting rights (compared to
48,604,973 outstanding ordinary shares previously). This number
will be used as the denominator for the calculation of the
percentages of shareholdings.
In addition, Oxurion has reimbursed EUR 3
million (30%) of the Kreos/Pontifax Convertible Bonds issued in
December 2021. Within that framework, the cash covenant has been
reduced from EUR 4 million to EUR 3 million and the interest-only
period has been extended until the end of the third quarter of
2022. The reimbursement reduces the total number of shares to be
issued upon a potential conversion of the Kreos/Pontifax
Convertible Bonds by 1,034,482 shares without impacting the cash
runway included in the Company’s Prospectus issued in March
2022.
Therefore, Oxurion publishes the following
updated information:
|
69,456,161.32 |
- Total number of securities with
voting rights (all ordinary shares)
|
49,821,189 |
- Total number of ordinary shares (=
denominator)
|
49,821,189 |
- Number of outstanding rights to
subscribe to securities carrying voting rights not yet issued:
|
|
- 751,500 subscription rights (“SRs”)
issued on November 20, 2017, entitling their holders to subscribe
to a total number of 751,500 securities carrying voting rights (all
ordinary shares);
- 60,000 SRs issued on December 23,
2020, entitling their holders to subscribe to a total number of
60,000 securities carrying voting rights (all ordinary
shares);
- 1,010,000 SRs issued on April 14,
2021, entitling their holders to subscribe to a total number of
1,010,000 securities carrying voting rights (all ordinary
shares);
- 550,000 SRs issued on September 22,
2021, entitling their holders to subscribe to a total number of
550,000 securities carrying voting rights (all ordinary
shares);
- 100 convertible bonds issued on
December 20, 2021, entitling their holders (Kreos Capital VI (UK)
Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax
Medison Finance (Cayman) L.P.) to subscribe to a total number of
securities carrying voting rights (all ordinary shares) in
accordance with the terms and conditions of these convertible bonds
as attached to the Agreement for the provision of a Loan Facility
entered into between the Company, Kreos Capital VI (UK) Limited,
Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance
(Cayman) L.P., on November 21, 2021 and as amended following the
partial reimbursement in June 2022;
- 724,749 SRs issued on December 30,
2021, entitling their holders to subscribe to a total number of
724,749 securities carrying voting rights (all ordinary shares);
and
- 220 convertible
bonds issued on April 29, 2022, entitling their holder (Negma
Group) to subscribe to a total number of securities carrying voting
rights (all ordinary shares) in accordance with the terms and
conditions set forth in the Issuance and subscription agreement
entered into between the Company and Negma Group on August 26,
2021.
|
END
About
Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michaël DillenChief Business
OfficerTel: +32 479 783 583michael.dillen@oxurion.com |
USConway CommunicationsBeth
Kurthbkurth@conwaycommsir.com ICR WestwickeChristopher
BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com |
- OXUR PR_Voting rights (ENG)_20220630
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024